Buscar

Mostrando ítems 1-10 de 10

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: a post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies

2019- Taylor, P. C.; van de Laar, M.; Curtis, J. R.; Azevedo, V. F.; Rivas, J. L.; [et al.]

Effect of smoking on the efficacy of TNF inhibitors in the treatment of chronic inflammatory inmune-mediated diseases: systematic review and meta-analysis

2019- Dos Santos Sobrín, Raquel; Souto Vilas, Alejandro; Fernandez, J. R. M.; Mera Varela, Antonio; Gómez-Reino Carnota, Juan Jesús

Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

2019- Ferreiro Iglesias, Aida; Montes, A.; Pérez Pampín, Eva; Cañete, J. D.; Raya, E.; [et al.]

Factors associated to persistence of treatment with golimumab in the biobadaser registry, with up to 6 years of follow-up

2019- POMBO SUAREZ, MANUEL ENRIQUE; Sanchez-Piedra, C.; Cuende, E.; Martin-Domenech, R.; del Pino, J.; [et al.]

Changing pattern of the use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

2019- Sanchez-Piedra, C.; Prior-Espanol, A.; Gonzalez, M. F.; Colazo, M.; Ruiz-Montesinos, D.; [et al.]

Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR

2019- Ranza, R.; de la Vega, M. C.; Laurindo, I. M. M.; Gómez, M. G.; Titton, D. C.; [et al.]

Impact of age on the appearance of adverse eventsat the beginning of biological treatment: data from the BIOBADASER 3.0 registry

2019- Vela-Casasempere, P.; Sanchez-Piedra, C.; Perez-Garcia, C.; Arija, S. M.; Villegas, M. D. C.; [et al.]

Effectiveness of biologic therapy on disease activity in ankylosing spondylitis: a BIOBADASER III observational study

2019- Emperiale, V.; Sanchez-Piedra, C.; Bohorquez, C.; Colazo, M.; Fernandez-Lopez, C.; [et al.]

Survival of jak inhibitors: real-word data from the biobadaser III registry

2019- Emperiale, V.; Sanchez-Piedra, C.; Cuende, E.; Vela-Casasempere, P.; Villegas, M. D. C.; [et al.]

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment

2019- Genovese, M. C.; van der Heijde, D.; Lin, Y.; St John, G.; Wang, S.; [et al.]